Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 4;3(1):30.
doi: 10.1186/2110-5820-3-30.

Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

Jordi Masip  1 , Jaume Mesquida, Cecilia Luengo, Gisela Gili, Gemma Gomà, Ricard Ferrer, Jean Louis Teboul, Didier Payen, Antonio Artigas
Affiliations

Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

Jordi Masip et al. Ann Intensive Care. .

Abstract

Background: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study explored the utility of thenar muscle oxygen saturation (StO2) and its changes during a transient vascular occlusion test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients.

Methods: A prospective, observational study was performed in three general intensive care units at three university hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal contraindication. StO2 was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started and were repeated daily for a 96-hour period.

Results: Patients' characteristics, outcome, severity, and baseline values of StO2, DeOx, and ReOx did not differ between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91, p < 0.01).

Conclusions: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality with high sensitivity and specificity. Thus, StO2 derived variables might be useful to evaluate the microcirculatory response to treatment of septic shock.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution over time in treated and control patients. *p < 0.05 compared with T0; §p < 0.05 compared with control patients.
Figure 2
Figure 2
StO2-derived variables evolution: treated vs control group. A. DeOx evolution in treated and control patients. Mean and SE are represented. *p < 0.05 compared with T0; §p < 0.05 compared with control patients. B. ReOx evolution in treated and control patients. Mean and SE are represented. *p < 0.05 compared with T0; §p < 0.05 compared with control patients.
Figure 3
Figure 3
None of the VOT-derived variables was associated with early SOFA improvement. Mean and SE are represented. *p < 0.05 compared with T0.
Figure 4
Figure 4
StO2-derived variables evolution and outcome. A. DeOx evolution according to mortality. Mean and SE are represented. *p < 0.05 compared with T0; §p < 0.05 compared with nonsurvivors. B. ReOx evolution according to mortality. Mean and SE are represented. *p < 0.05 compared with T0; §p < 0.05 compared with nonsurvivors.
See this image and copyright information in PMC

References

    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;3:1303–1310. doi: 10.1097/00003246-200107000-00002. - DOI - PubMed
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;3:1368–1377. doi: 10.1056/NEJMoa010307. - DOI - PubMed
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent J-L. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;3:17–60. doi: 10.1007/s00134-007-0934-2. - DOI - PMC - PubMed
    1. De Backer D, Creteur J, Preiser J-C, Dubois M-J, Vincent J-L. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;3:98–104. doi: 10.1164/rccm.200109-016OC. - DOI - PubMed
    1. Sakr Y, Dubois M-J, De Backer D, Creteur J, Vincent J-L. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;3:1825–1831. doi: 10.1097/01.CCM.0000138558.16257.3F. - DOI - PubMed

LinkOut - more resources